gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) Selected for Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) Program
19 Abril 2022 - 9:00AM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage
bioelectronic medicine company, today announced that
gammaCore™ nVNS has been selected for further study under the
United States Department of Defense Biotech Optimized for
Operational Solutions and Tactics (BOOST) program. The program,
which is expected to run through September 2023, is funded through
the BOOST program as well as the Defense Advanced Research Projects
Agency (DARPA).
The BOOST research program, which will be conducted under the
leadership of the 711 Human Performance Wing Performance
Optimization Branch of the United States Air Force (USAF), seeks to
optimize and validate the ability of nVNS to enhance training in
the intelligence, surveillance, and reconnaissance (ISR) training
environment. The BOOST program seeks to build upon completed work
which demonstrated that gammaCore nVNS produced 20% acceleration in
training along with a 35% improvement in memory retention during
ISR training. Participants in this study also exhibited a 25%
improvement in attention and mood1. Should the BOOST Program
confirm the initial findings, the project calls for electroCore to
be prepared to provide field ready devices to the USAF in the
second half of 2023.
Andy McKinley, Ph.D. of the United States Air Force Research
Laboratory (AFRL) and a principal investigator for the ongoing
research commented “We are pleased with results experienced to date
using nVNS and look forward to confirming our findings and
providing a safe and effective option to accelerate training for
our aviators and operators.”
Eric Liebler, Senior Vice President of Neurology at electroCore
commented, “We are very proud to have been selected for study by
the BOOST program and look forward to continuing supporting the 711
Human Performance Wing’s research throughout the next year.”
About AFRLThe Air Force Research Laboratory
(AFRL) is the primary scientific research and development center
for the Department of the Air Force. AFRL plays an integral role in
leading the discovery, development, and integration of affordable
warfighting technologies for our air, space and cyberspace force.
With a workforce of more than 11,000 across nine technology areas
and 40 other operations across the globe, AFRL provides a diverse
portfolio of science and technology ranging from fundamental to
advanced research and technology development.
For more information, visit: www.afresearchlab.com.
About electroCore, Inc.electroCore, Inc. is a
commercial stage bioelectronic medicine company dedicated to
improving patient outcomes through its non-invasive vagus nerve
stimulation therapy platform, initially focused on the treatment of
multiple conditions in neurology. The company's current indications
are the preventive treatment of cluster headache and migraine, the
acute treatment of migraine and episodic cluster headache, the
acute and preventive treatment of migraines in adolescents, and
paroxysmal hemicrania and hemicrania continua in adults.
For more information, visit www.electrocore.com.
About gammaCore™gammaCore™ (nVNS) is the
first non-invasive, hand-held medical therapy applied at the neck
to treat migraine and cluster headache through the utilization of a
mild electrical stimulation to the vagus nerve that passes through
the skin. Designed as a portable, easy-to-use technology, gammaCore
is self-administered by patients, as needed, without the potential
side effects associated with commonly prescribed drugs. When placed
on a patient’s neck over the vagus nerve, gammaCore stimulates the
nerve’s afferent fibers, which may lead to a reduction of pain in
patients.
gammaCore (nVNS) is FDA cleared in the United
States for adjunctive use for the preventive treatment of
cluster headache in adult patients, the acute treatment of pain
associated with episodic cluster headache in adult patients, and
the acute and preventive treatment of migraine in adolescent (ages
12 and older) and adult patients, and paroxysmal hemicrania and
hemicrania continua in adult patients. gammaCore is CE-marked in
the European Union for the acute and/or prophylactic
treatment of primary headache (Migraine, Cluster Headache,
Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and
Medication Overuse Headache in adults.
gammaCore is contraindicated for patients if they:
- Have an active implantable medical device, such as a pacemaker,
hearing aid implant, or any implanted electronic device
- Have a metallic device, such as a stent, bone plate, or bone
screw, implanted at or near the neck
- Are using another device at the same time (e.g., TENS Unit,
muscle stimulator) or any portable electronic device (e.g., mobile
phone)
Safety and efficacy of gammaCore have not been evaluated in the
following patients:
- Adolescent patients with congenital cardiac issues
- Patients diagnosed with narrowing of the arteries (carotid
atherosclerosis)
- Patients who have had surgery to cut the vagus nerve in the
neck (cervical vagotomy)
- Pediatric patients (less than 12 years)
- Pregnant women
- Patients with clinically significant hypertension, hypotension,
bradycardia, or tachycardia
For more information, please visit gammaCore.com
Forward-Looking StatementsThis press release
and other written and oral statements made by representatives of
electroCore may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include, but are not limited to,
statements about electroCore's business prospects and clinical and
product development plans (including with respect to enrollment in
ongoing studies and Department of Defense programs); its pipeline
or potential markets for its technologies including the USAF and
other branches of the military; the timing, outcome and impact of
regulatory, clinical and commercial developments including online,
e-commerce, direct-to-consumer channels, telehealth portal, and
cash pay initiatives; the issuance of U.S. and international
patents providing expanded IP coverage; the possibility of future
business models and revenue streams from the company’s potential
use of nVNS for the acute treatment of PTSD, stroke and hemorrhagic
brain injury, the potential of nVNS generally and gammaCore in
particular and other statements that are not historical in nature,
particularly those that utilize terminology such as "anticipates,"
"will," "expects," "believes," "intends," other words of similar
meaning, derivations of such words and the use of future dates.
Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the ability to raise the additional funding
needed to continue to pursue electroCore’s business and product
development plans, the inherent uncertainties associated with
developing new products or technologies, the ability to
commercialize gammaCore™, the potential impact and effects of
COVID-19 on the business of electroCore, electroCore’s results of
operations and financial performance, and any measures electroCore
has and may take in response to COVID-19 and any expectations
electroCore may have with respect thereto, competition in the
industry in which electroCore operates and overall market
conditions. Any forward-looking statements are made as of the date
of this press release, and electroCore assumes no obligation to
update the forward-looking statements or to update the reasons why
actual results could differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents electroCore files with the SEC available at
www.sec.gov.
__________________________________1 McIntire LK, McKinley RA,
Goodyear C, et al. Cervical transcutaneous vagal nerve stimulation
(ctVNS) improves human cognitive performance under sleep
deprivation stress. Communications Biology. 2021;634. doi:
10.1038/s42003-021-02145-7
Contact:Rich CockrellCG
Capital404-736-3838ecor@cg.capital
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024